Neoleukin Therapeutics, Inc. Banner Image

Neoleukin Therapeutics, Inc. has reached its limit for free report views

Work for Neoleukin Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Neoleukin Therapeutics, Inc.

  • Ticker NLTX
    Exchange NASDAQ More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
Neoleukin Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Seattle, Washington
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidateMore, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface.
Neoleukin Therapeutics, Inc.

Most Recent Annual Report

Neoleukin Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Neoleukin Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports